A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma

Conditions

Bladder | Cancer

What is the purpose of this trial?

  • To evaluate the overall survival following administration of DN24-02
  • To evaluate disease free survival following administration of DN24-02
  • To evaluate the safety of DN24-02
  • To evaluate the magnitude immune response induced by administration of DN24-02
  • To evaluate the magnitude of cumulative CD54 upregulation following administration of DN24-02

Participation Guidelines

Age:
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Dendreon Corporation
Dates:
06/20/2013
Last Updated:
Study HIC#:
1301011399